인슐린 투여 기기 시장 요약
인슐린 투여 기기 시장 성장 촉진요인
본 보고서는 세계의 인슐린 투여 기기 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 법규제 환경, 시장 규모 추이와 예측, 각종 구분, 지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업프로파일 등을 정리했습니다.
Insulin Delivery Devices Market Summary
Factors Contributing to the Growth of the Insulin Delivery Devices Market
Insulin Delivery Devices Market Report Segmentation
This insulin delivery devices market report offers a comprehensive overview of the global insulin delivery devices market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Product Type (Insulin Syringes, Insulin Pens [Reusable Insulin Pens and Disposable Insulin Pens], Insulin Pumps [Tethered/External Pumps and Patch Pumps], Insulin Injectors, and Others), End-User (Homecare Settings, Diabetes Centers, Hospitals, and Others), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing insulin delivery devices market.
Insulin delivery devices are medical tools used by people with diabetes to administer insulin, a hormone that helps regulate blood sugar levels. Since insulin cannot be taken orally, these devices provide a way to inject or deliver it into the body, typically into the subcutaneous (fatty) tissue.
These devices have evolved significantly over the years, moving from simple syringes to more advanced and automated systems. The choice of device depends on a person's specific insulin regimen, lifestyle, dexterity, vision, and personal preference.
The overall insulin delivery devices market is being boosted by a combination of factors, including the rising prevalence of diabetes, growing preference for home-based management, increased patient awareness and education, ongoing technological advancements in device design, and active product development by key market players. Together, these factors are driving higher adoption of innovative, convenient, and efficient insulin delivery solutions worldwide.
What are the latest Insulin Delivery Devices Market Dynamics and Trends?
The global market for insulin delivery devices is experiencing significant growth, driven by a confluence of rising diabetes prevalence and the increasing adoption of home-based diabetes management.
The escalating number of people diagnosed with diabetes is the primary driver of market expansion. According to recent data, approximately 591 million people worldwide were living with diabetes in 2025. Projections indicate this number could rise to around 854 million by 2050, representing a substantial 46% increase. With over 90% of these cases being Type 2 diabetes, a larger patient population requires effective and convenient solutions for regular insulin administration, fuelling demand for a diverse range of delivery devices.
Additionally, the shift from traditional hospital-based treatment to convenient home-based diabetes management is a major catalyst for market growth. Modern insulin delivery devices, such as insulin pens, patch pumps, and automated systems, empower patients to self-manage their condition safely and discreetly, reducing the need for frequent hospital visits. These devices improve patient adherence to treatment plans and facilitate remote monitoring by healthcare providers, driving a higher demand for innovative technologies. For example, in March 2024, the FDA cleared the Sequel Twist AID System, the first automated insulin delivery (AID) system to directly measure insulin delivery volume and flow, which enhances the rapid detection of blockages and other issues.
Technological advancements have also reshaped the industry, as the industry is experiencing a notable shift towards wearable and automated insulin delivery (AID) devices. Insulin pumps and patch pumps offer continuous insulin infusion, providing greater convenience and discretion for users. A key development in this space is the push for regulatory approvals. For instance, in January 2024, PharmaSens, a Swiss medical device company, submitted an FDA application for its 'niia essential' insulin patch pump system. This application, following its ISO 13485 certification in November 2023, is a significant step toward making advanced, patient-centric insulin pump technology more widely available.
However, the market's growth faces several challenges. The presence of effective oral medications for diabetes and an increased number of product recalls pose challenges. Additionally, high costs, limited reimbursement in certain regions, and a steep learning curve for advanced technologies may limit adoption, particularly among older patients or those in developing economies. The lack of interoperability between devices and patient apprehension towards needles also present persistent hurdles that the industry must address.
Insulin Delivery Devices Market Segment Analysis
Insulin Delivery Devices Market by Product Type (Insulin Syringes, Insulin Pens [Reusable Insulin Pens and Disposable Insulin Pens], Insulin Pumps [Tethered/External Pumps and Patch Pumps], Insulin Injectors, and Others), End-User (Homecare Settings, Diabetes Centers, Hospitals, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
By Product Type: Insulin Pens Category Dominates the Market
The insulin pens segment holds a dominant position in the insulin delivery devices market, capturing a substantial 45% share in 2024. This leadership is primarily attributed to the widespread adoption of reusable insulin pens, which are projected to hold the largest market share within this segment. Reusable pens are gaining popularity for a variety of compelling reasons. They offer significant cost-effectiveness and are more environmentally friendly, as they allow patients to replace insulin cartridges without discarding the entire device. Beyond these benefits, they provide enhanced dosing accuracy, improved ease of use, and customizable features, all of which contribute to better adherence to insulin therapy.
The rise of reusable pens also reflects a broader shift towards more advanced and connected diabetes management. Recent advancements in their design, such as improved ergonomics, integrated memory functions to track dose history, and seamless integration with digital health platforms, have made them increasingly appealing to tech-savvy patients and healthcare providers.
This trend is particularly strong in developed regions with advanced healthcare infrastructure and higher disposable incomes, where patients value long-term usability and sustainability. For example, in May 2025, GO-Pen ApS received FDA 510(k) clearance for the GO-PEN(R), a user-filled pen that is compatible with standard insulin vials. This innovation provides a more affordable and sustainable alternative to traditional pens, demonstrating how the industry is evolving to address both cost and environmental concerns. The continued development and approval of such devices are expected to further boost the market for reusable insulin pens, thereby strengthening the overall insulin delivery devices market.
By End-User: Homecare Settings Dominates the Market
Home care settings are playing a crucial role in boosting the insulin delivery devices market by enabling patients to manage diabetes more independently and effectively in the comfort of their homes. With devices such as reusable insulin pens, insulin pumps, and smart delivery systems, patients can achieve accurate dosing, maintain better glycemic control, and reduce reliance on frequent hospital visits. This shift toward home-based care improves convenience, lowers healthcare costs, and supports patient adherence to long-term therapy. Moreover, the integration of digital health tools and remote monitoring in home care settings further enhances disease management, driving higher demand for advanced insulin delivery devices.
Insulin Delivery Devices Market Regional Analysis
North America Insulin Delivery Devices Market Trends
North America is the dominant force in the global insulin delivery devices market, holding a substantial 36% market share in 2024. This leadership position is driven by a combination of a high burden of diabetes, a robust healthcare infrastructure, and a strong culture of adopting innovative medical technologies.
The foundation of this market dominance is the significant prevalence of diabetes in the region. According to the Centers for Disease Prevention and Control (CDC), over 38.4 million people, or 11.6% of the U.S. population, were living with diabetes in 2024. This massive patient pool requires daily insulin therapy, making advanced devices like smart insulin pens, patch pumps, and automated insulin delivery (AID) systems essential for disease management. The U.S. also leads in healthcare expenditure, which, combined with favorable reimbursement policies, allows for greater access to these sophisticated and often costly devices.
Beyond prevalence, several interconnected factors contribute to the region's market leadership. The mature healthcare infrastructure facilitates the seamless integration of new devices into clinical practice. Additionally, proactive diabetes awareness programs play a crucial role. Initiatives from organizations like the CDC educate both patients and healthcare providers on the benefits of proactive care and the latest technological advancements. This not only promotes early diagnosis but also drives the adoption of advanced devices, as patients become more informed about their options for self-management.
Finally, a highly competitive landscape, marked by continuous research and development, further solidifies North America's position. The presence of numerous key market players actively involved in product development, strategic partnerships, and mergers and acquisitions fuels innovation. For example, Embecta Corp.'s submission of a 510(k) premarket application for a new disposable insulin delivery system and Beta Bionics' FDA approval for its iLet ACE Insulin Pump in 2023 illustrate the ongoing commitment to bringing next-generation devices to market. This dynamic environment ensures a steady stream of cutting-edge products, reinforcing the region's market dominance during the forecast period.
Europe Insulin Delivery Devices Market Trends
Europe is a significant driver of the insulin delivery devices market, fueled by its robust healthcare infrastructure, rising diabetes prevalence, and a strong preference for advanced, connected technologies. The region faces a growing diabetes epidemic; according to the International Diabetes Federation, approximately 59.8 million people in Europe were living with diabetes in 2024, with that number projected to increase to 72.4 million by 2050. This demographic shift has created a pressing need for effective and accessible diabetes management tools. In response, European countries are actively promoting early diagnosis and proactive care through awareness campaigns and favorable reimbursement policies, which have encouraged the adoption of innovative solutions like reusable pens, insulin pumps, and smart devices.
Furthermore, patient and provider preferences for eco-friendly, cost-effective, and technologically advanced options are fueling market expansion. This is evident in the push for devices that offer greater connectivity and convenience. The integration of digital health platforms and telemedicine is a key trend, allowing for real-time data sharing between patients and healthcare providers. This not only improves treatment adherence but also enables remote monitoring and personalized care, which is particularly vital for chronic conditions like diabetes.
The European market is also a hub for innovation, with leading manufacturers continually launching new products and expanding the indications for existing ones. A prime example is Medtronic plc, which in July 2025 received CE Mark approval to expand the use of its MiniMed(TM) 780G system. This pivotal approval allows the automated insulin delivery (AID) system to be used by a much broader patient population, including individuals as young as two, pregnant women, and people with insulin-requiring Type 2 diabetes. This expansion, based on rigorous clinical data, highlights a commitment to making advanced technology available to a more diverse range of patients, thereby solidifying Europe's role as a key growth driver in the global insulin delivery devices market.
Asia-Pacific Insulin Delivery Devices Market Trends
The Asia-Pacific region is emerging as a key growth driver in the insulin delivery devices market, propelled by a rapidly escalating prevalence of diabetes. This surge is a direct result of urbanization, increasingly sedentary lifestyles, and evolving dietary habits across the region. Countries with vast populations, such as China and India, are at the forefront of this trend, creating a massive demand for effective and convenient insulin delivery solutions like pens, pumps, and smart devices. For example, recent studies in India estimated that 77 million people over the age of 18 were living with Type 2 diabetes, with an additional 25 million considered prediabetic. This significant patient pool makes advanced insulin delivery systems essential for managing the disease and improving patient outcomes.
Governments and healthcare organizations are proactively responding to this health crisis. They are actively investing in diabetes awareness campaigns, promoting early diagnosis, and improving access to treatment. These initiatives, combined with expanding healthcare infrastructure, are accelerating a fundamental shift from conventional insulin delivery methods to modern, user-friendly systems. Additionally, the increasing presence of global market players is strengthening the market's growth. These companies are establishing local partnerships and gaining regulatory approvals for their innovative products, ensuring a steady supply of cutting-edge technology. For instance, the collaboration between global and local firms is not only improving product availability but also adapting devices to regional needs, such as a greater focus on affordability and home-based care.
Furthermore, the growing adoption of digital health platforms and telemedicine is transforming diabetes care in the region. These technologies enhance patient adherence and convenience by enabling remote monitoring, real-time data analysis, and personalized treatment plans. Collectively, these factors, from the demographic shift and government support to technological innovation and strategic partnerships, position Asia-Pacific as one of the fastest-growing regions for insulin delivery devices, offering significant opportunities for market expansion.
Who are the major players in the insulin delivery devices market?
The following are the leading companies in the insulin delivery devices market. These companies collectively hold the largest market share and dictate industry trends.
How is the competitive landscape shaping the Insulin Delivery Devices market?
The insulin delivery devices market is mainly dominated by a few big companies like Medtronic, Insulet, Tandem, Novo Nordisk, Sanofi, Eli Lilly, Roche, and Ypsomed, which makes the market highly concentrated. These companies stay ahead by offering advanced technologies such as automated insulin systems, tubeless pumps, and smart reusable pens, along with digital platforms that connect devices to apps and cloud systems. Smaller players and startups are also entering the market with affordable or specialized products, especially in price-sensitive regions, which adds some competition. However, the big players hold the most influence because of their strong research, global presence, and ability to secure regulatory approvals and insurance coverage. Overall, competition is moving beyond just devices to offering complete diabetes care solutions, including digital health and remote monitoring.
Recent Developmental Activities in the Insulin Delivery Devices Market
Insulin Delivery Devices Market Segmentation
Impact Analysis
AI-Powered Innovations and Applications:
Artificial Intelligence (AI) is transforming insulin delivery devices by enhancing precision, adaptability, and user convenience. Advanced AI-powered systems, such as Medtronic's MiniMed(TM) 780G, automatically adjust insulin delivery in real time based on continuous glucose monitoring (CGM) data, helping maintain blood glucose within target ranges and reducing the need for manual intervention. Other innovations include neural network-based systems that detect meals and recommend insulin doses to improve postprandial glucose control, and fully automated devices like Beta Bionics' iLet Bionic Pancreas, which learns individual insulin needs without requiring carb counting or manual corrections. AI-driven digital twin technologies, such as GlyTwin, simulate a patient's glucose response to lifestyle and dietary factors, providing personalized recommendations for optimal insulin therapy. In inpatient settings, systems like Glucommander use AI to automate intravenous insulin dosing, improving efficiency and reducing human error. Collectively, these AI-powered applications are making insulin delivery more personalized, efficient, and effective, and ongoing advancements are expected to further enhance patient outcomes and ease of diabetes management.
U.S. Tariff Impact Analysis on Insulin Delivery Devices Market:
The recent U.S. tariffs on medical devices, including insulin delivery systems, have introduced several challenges for both manufacturers and patients. These tariffs, which affect a significant portion of medical devices, have led to increased production costs for companies that rely on imported components. Manufacturers are responding by exploring strategies to mitigate these costs, such as optimizing supply chains and adjusting manufacturing operations. However, these adjustments may not fully offset the increased expenses, potentially leading to higher prices for consumers. This price increase could result in reduced access to essential diabetes management tools for patients, particularly those without comprehensive insurance coverage. Physicians have expressed concern that these tariffs may exacerbate existing affordability issues, leading some patients to delay or forgo necessary treatments. In summary, the U.S. tariffs on medical devices are contributing to increased production costs, which may translate into higher prices for insulin delivery systems. This situation poses a risk to patient access and adherence to diabetes management regimens, highlighting the need for careful consideration of trade policies in the healthcare sector.
How This Analysis Helps Clients
Key takeaways from the insulin delivery devices market report study
Frequently Asked Questions for the Insulin Delivery Devices Market